Investor Relations

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

View company overview

News releases

View all
Apr 09, 2026

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11 th, 2026.

Read more
Mar 03, 2026

Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.  RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ®

Read more
Feb 27, 2026

RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46 th Annual Health Care Conference Date and Time: Tuesday, March

Read more